A Study on The Patients Perspectives and Social Aspects on Disease-Modifying Antirheumatic Drugs in The Treatment of Rheumatoid Artritis in Turkey

Abstract

The aim of the study is to provide a comprehensive assessment of “patient perspectives and social aspects” dimension of Health Technology Assessment Method for DMARDs, used in treatment of Rheumatoid Arthritis (RA) in Turkey. Delphi panel technique and interviews with representatives of patients’ associations were used to collect data. As a result of the study, it was observed that there was no difference between individuals within the scope of social security institutions in terms of access to DMARDs, but there were regional differences regarding access to rheumatologists due to their low number. The study also found that patients did not face any significant social or economic barriers to accessing DMARDs, but their knowledge of RA was both insufficient and unequal among patients. A full understanding of the benefit and safety of treatment by patients; Adherence to treatment is important for achieving the planned goal and the success of policies created for RA management. Therefore, at all levels of disease management, it would be beneficial to consider joint decision-making by the patient / caregiver-physician, the use of informed consent forms and the vital role of health professionals.

Keywords

• Health Technology Assessment
• Rheumatoid Arthritis
• DMARDs
• Patient Perspectives
• Social Aspects

A Study on The Patients Perspectives and Social Aspects on Disease-Modifying Antirheumatic Drugs in The Treatment of Rheumatoid Artritis in Turkey

Abstract

References

1. Arthritis Foundation (2020). Arthritis by the numbers Book of Trusted Facts & Figures 2020. https://www.arthritis.org/getmedia/73a9f02d-7f91-4084-91c3-0ed0b11c5814/abtn-2020-final.pdf.
2. Bozbas, GT., Gurer, G. (2018). The Knowledge Level of Turkish Rheumatoid Arthritis Patients about Their Diseases. Anadolu Kliniği Tıp Bilimleri Dergisi, Ocak 2018; Cilt 23, Say 1.
3. Bridges, JFP. and Jones, C. (2007). Patient-based health technology assessment: A vision of the future International Journal of Technology Assessment in Health Care, 23:1 (2007), 30–35. Cambridge University Press. U.S.A.
4. EUnetHTA (2016). Joint Action on HTA 2012-2015 HTA Core Model Version 3.0 25 Jan 2016HTA Core Model Version 3.0. Access:21 June 2019.https://eunethta.eu/wp-content/uploads/2018/03/HTACoreModel3.0-1.pdf.
5. Facey, K., Boivin, A., Gracia, J., et al. (2010) Patients' perspectives in health technology assessment: A route to robust evidence and fair deliberation. International Journal of Technology Assessment in Health Care 26(3):334-40 July 2010.
6. Gagnon, MP., Desmartis, M., Lepage-Savary, D., Gagnon, J., St-Pierre, M., Rhainds, M., et al. (2011). Introducing patients’ and the public’s perspectives to health technology assessment: A systematic review of international experiences. International Journal of Technology Assessment in Health Care, 27:1 (2011), 31–42. Cambridge University Press 2011.
7. Hennell, L., Brownsel, C. Dawson, JK. (2004). Development, validation and use of a patient knowledge questionnaire (PKQ) for patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:467-71.
8. Helliwell, PS., O’hara, M. Holdsworth, J. Hesselden, A., King, T., Evans, P. (1999). A 12-month randomized controlled trial of patient education on radiographic changes and quality of life in early rheumatoid arthritis. Rheumatology (Oxford) 1999;38:303-8.

9. Kleme, J., Pohjanoksa-Mantyla, M., Airaksinenet, M., Enlund, H., Kastarinen, H., Peura, P., et al. (2014). Patient Perspective in Health Technology Assessment of Pharmaceuticals in Finland. International Journal of Technology Assessment in Health Care, 30:3 (2014), 306–311. Cambridge University Press 2014.
10. Kockaya, G., Yenilmez, FB., Sharaf, A., et al. (2017). Increasing Trend On Turkish Un-Licenced Medicine Market: A General Overview Analysis. Abstract Only| Volume 20, Issue 9, Pa668-A669, October 01, 2017.
11. Listing, J., Gerhold, K., Zink, A. (2013). The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment Rheumatology, Volume 52, Issue 1, January 2013, Pages 53–61, https://doi.org/10.1093/rheumatology/kes305. Mäkeläinen, P., Vehviläinen-Julkunen, K., Pietilä, M. (2009). Rheumatoid arthritis patients' knowledge of the disease and its treatments: A descriptive study. Musculoskeletal care. 7. 31-44. 10.1002/msc.138.
12. Maggs, FM., Jubb, RW., Kemm, J.R., (1996). Single-blind randomised controlled trial of an educational booklet for patients with chronic arthritis. Br J Rheumatol 1996;35:775-7.
13. Matcham, F., Scott, IC., Rayner, L., Hotopf, M., Kingsley, GH., Norton, S. et al. (2014). The impact of rheumatoid arthritis on quality-of-life assessed usingthe SF-36: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 44 (2014) 123–130.
14. Mithani, Z. (2012). Virtual Mentor, 012;14(7):576-581, doi:10.1001/virtualmentor.2012.14.7.oped1-1207.
15. National Library of Medicine, (n.d). HTA 101: Introduction to Health Technology Assessment, https://www.nlm.nih.gov/nichsr/hta101/ta10103.html. NHS (n.d.). Symtoms, Rheumatoid arthritis.https://www.nhs.uk/conditions/rheumatoid-arthritis/symptoms/.
16. Nörobilim (2020). Türk Romatologlar Danimarkalı Hekimlere Türkiye’de Sık Görülen İnflamatuar Hastalıkları Anlattılar. https://norobilim.com/turk-romatologlar-danimarkali-hekimlere-turkiyede-sik-gorulen-inflamatuar-hastaliklari-anlatti/.
17. OECD (2017). “Population coverage for health care”, in Health at a Glance 2017: OECD Indicators, OECD Publishing, Paris.
18. Sandman, L., Granger, BB., Ekman, I., Munthe, C. (2012). Adherence, shared decision-making and patient autonomy. Med Health Care Philos. 2012 May;15(2):115-27. doi: 10.1007/s11019-011-9336-x. PMID: 21678125.
19. Sierakowska, M., Klepacka, M., Sierakowski, SJ., Pawlak-Buś, K., Leszczyński, P., Majdan, M., et al. (2016). Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems - A cross-sectional study. Ann Agric Environ Med 2016;23:361-7.
20. Singh, JA., Saag, KG., Bridges, SL., Akl, EA., Bannuru, RR., Sullivan, MC. et al. (2015). Arthritis & Rheumatology, Vol. 68, No. 1, January 2016, pp 1–26. DOI 10.1002/art.39480VC2015.
21. Sorenson, C., Drummond, M. Kanavos, P. (2008). Ensurıng Value For Money In Health Care The role of health technology assessment in the European Union. Observatory Studies Series No 11. https://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf.
22. Sorenson, C., Drummond, M., Kristensen, FB., Busse, R. (2008(. How can the impact of health technology assessments be enhanced? World Health Organization 2008 and World Health Organization, on behalf of the European Observatory on Health Systems and Policies 200 https://www.euro.who.int/__data/assets/pdf_file/0019/73225/E93420.pdf8 .
23. Talibova, A. (2015). Romatoid Artrit Hastalarında Ve Birinci Derece Akrabalarında Yaşam Kalitesinin Değerlendirilmesi, Uzmanlık Tezi. T.C. Trakya Üniversitesi Tıp Fakültesi Fizik Tedavi Ve Rehabilitasyon Anabilim Dalı, Edirne.
24. World Health Organization (n.d.). Chronic rheumatic conditions, https://www.who.int/chp/topics/rheumatic/en/Fet. Whitney, SN., McGuire, AL., McCullough, LB. (2003). A Typology of Shared Decision Making, Informed Consent, and Simple Consent, Ann Intern Med. 2003;140:54-59